A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Lebrikizumab (Primary) ; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical; Roche
- 16 Nov 2017 Status changed from active, no longer recruiting to completed.
- 25 Oct 2017 This study has been completed in Spain as per European Clinical Trials Database.
- 20 Jul 2017 Planned End Date changed from 14 Nov 2017 to 15 Nov 2017.